PLENAXIS Drug Patent Profile

« Back to Dashboard

When do Plenaxis patents expire, and what generic alternatives are available?

Plenaxis is a drug marketed by Speciality European and is included in one NDA.

The generic ingredient in PLENAXIS is abarelix. Additional details are available on the abarelix profile page.

Summary for PLENAXIS

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PLENAXIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Speciality European	PLENAXIS	abarelix	POWDER;INTRAMUSCULAR	021320-001	Nov 25, 2003		DISCN	No	No

International Patents for PLENAXIS

See the table below for patents covering PLENAXIS around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	222924
Austria	432941
Australia	6168096
Australia	715399
Canada	2219460	PEPTIDES ANTAGONISTES DE LA LH-RH (LHRH ANTAGONIST PEPTIDES)
Germany	122006000012
Germany	69535963

Supplementary Protection Certificates for PLENAXIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0794961	91225	Luxembourg		91225, EXPIRES: 20200922
0794961	91857	Luxembourg		91857, EXPIRES: 20200922
0794961	C300484	Netherlands		PRODUCT NAME: ABARELIX, EVENTUEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 104389 20101220; FIRST REGISTRATION: 57890.00.00 20050922
0794961	CR 2011 00004	Denmark		PRODUCT NAME: ABARELIX, EVENTUELT I FORM AF ET FARMACEUTISK SALT; NAT. REG. NO/DATE: 44637 (DK) 20100827; FIRST REG. NO/DATE: DE 578900000 20050922
0794961	SPC/GB11/006	United Kingdom		PRODUCT NAME: ABARELIX, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE - 20050922; UK PL32828/001 20100917
0794961	CA 2011 00004	Denmark
0794961	1190014-9	Sweden		PRODUCT NAME: ABARELIX

Investment Scenario and Fundamentals Analysis for PLENAXIS

Last updated: February 20, 2026

What is PLENAXIS?

PLENAXIS (generic: velmanase alfa) is a recombinant enzyme therapy approved for the treatment of alpha-mannosidosis. It addresses a rare lysosomal storage disorder characterized by enzyme deficiency that causes accumulation of mannose-rich oligosaccharides. Approved by the FDA in 2019, PLENAXIS's primary indication is for pediatric patients with this condition.

Market Overview

Market Size and Penetration

• Prevalence: Alpha-mannosidosis affects approximately 1 in 500,000 to 1 million live births. Estimated patient count in the U.S.: 100–200.
• Treatment Penetration: As a rare disease therapy, market penetration is initially low. Orphan drug designation grants seven years of market exclusivity in the U.S.
• Pricing and Revenue: List price per patient ranges from $300,000 to $500,000 annually. Estimated peak global revenue (by 2030): $250 million to $500 million.

Competition

• Existing therapies: No approved alternatives for alpha-mannosidosis.
• Pipeline: Limited, with potential enzyme therapy candidates under development by small biotech firms. Regulatory and commercial barriers slow entry.

Clinical and Regulatory Fundamentals

Efficacy Data

• Clinical trials: Phase 1/2 data demonstrated reduction in oligosaccharide accumulation and improvements in motor and cognitive function.
• FDA approval: Based on a single-arm trial with 12 patients showing safety and biomarker improvements.

Safety Profile

• Adverse events: Mild to moderate infusion-related reactions. No significant safety concerns identified.
• Long-term safety: Data limited; ongoing studies required to confirm durability and safety profile.

Regulatory Status

Region	Status	Notes
US	Approved (2019)	Orphan drug designation, market exclusivity 7 years
EU	Not approved yet	Under review by EMA
Japan	Not filed yet	Potential future entry

Investment Fundamentals

Revenue Drivers

• Patient Access: Slow onboarding due to diagnosis delay and access barriers.
• Pricing Strategy: Premium pricing justified by orphan status, small patient populations.
• Market Expansion: Limited unless indication broadened; early engagement with regulators under Orphan Drug Act.

Cost Structure

• Manufacturing: High costs due to complex bioreactor production of recombinant enzymes.
• R&D: Ongoing investments in long-term safety studies and potential label expansion.
• Commercial: Focused on specialized centers; distribution channels limited.

Financial Outlook

An analysis indicates that revenue growth hinges on:

• Pricing guarantee and payer reimbursement policies.
• New patient identification programs.
• Potential off-label use or expanded indications.

Current sales estimates for PLENAXIS in 2023 remain below $50 million, with potential to reach $200–$300 million by 2030 if the product gains broader adoption.

Investment Risks

• Market size limitations: The small patient base caps revenue potential.
• Regulatory risks: Slow approval processes outside the US could delay revenue.
• Pricing pressures: Payer negotiations might limit reimbursement levels.
• Competitive developments: New therapies or gene editing modalities could threaten market share.

Key Factors Impacting Investment Decisions

• Market exclusivity until 2026, after which biosimilar or generic competition could emerge.
• The company's ability to expand access and demonstrate long-term efficacy.
• Regulatory pathways in other jurisdictions, especially the EU and Japan.
• Potential for label extension to other lysosomal storage disorders.

Key Takeaways

• PLENAXIS is a niche orphan drug addressing a rare disease with limited but stable revenue potential.
• The drug benefits from regulatory exclusivity and high per-patient pricing.
• Revenue growth depends on early diagnosis, market penetration, and payer acceptance.
• Significant risks include market size limitations, approval delays, and competitive threats.

FAQs

1. What is the primary therapeutic benefit of PLENAXIS?
It reduces oligosaccharide accumulation and improves motor and cognitive functions in patients with alpha-mannosidosis.

2. What are the main regulatory milestones for PLENAXIS?
FDA approval in 2019; potential EMA approval based on ongoing review; market expansion opportunities depend on additional approvals.

3. How does PLENAXIS compare to similar enzyme replacement therapies?
It is unique for alpha-mannosidosis, as no approved therapies currently exist, giving it a first-to-market advantage.

4. What are the key financial risks for investors?
Limited market size and payer negotiation pressures could restrict revenue growth.

5. What future developments could influence PLENAXIS’s valuation?
Label expansion, new clinical trial data, and approvals in additional markets.

---

References

[1] U.S. Food and Drug Administration. (2019). FDA approves first treatment for alpha-mannosidosis.
[2] Company filings and investor reports.
[3] Market intelligence reports on rare disease therapeutics.
[4] FDA Orphan Drug Designation Program.
[5] European Medicines Agency. (n.d.). Assessment status of velmanase alfa.